EMB07

Clinical trials for EMB07 explained in plain language.

Never miss a new study

Get alerted when new EMB07 trials appear

Sign up with your email to follow new studies for EMB07, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New antibody combo targets tough lymphoma in early trial

Disease control Not yet recruiting

This study tests a new drug called EMB-07, a bispecific antibody that helps the immune system attack cancer cells. It is for adults with aggressive B-cell non-Hodgkin lymphoma, either newly diagnosed or that has returned after treatment. The trial will check safety, side effects,…

Matched conditions: EMB07

Phase: PHASE1, PHASE2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control

Last updated May 11, 2026 20:50 UTC

EMB07

Get alerted when new EMB07 trials appear

New antibody combo targets tough lymphoma in early trial